Rocky start to South Korean positive list
This article was originally published in Scrip
The industry's early experiences with South Korea's proposed positive list reimbursement scheme have not been good, leading to some suggestions that it could be revised in the face of continuing opposition.
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.